Drug intelligence / Profile preview

XB014

Development stage: Preclinical
Lead developer: Exelixis
Modality: Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

XB014 is a development candidate, specifically a multispecific antibody, being developed for the treatment of cancer. It incorporates antibodies that were sourced from or developed in part with Invenra, Inc. as part of an active research collaboration with Exelixis.

Targets

CD47 (Cluster of Differentiation 47)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on XB014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XB014.

Explore the full profile